All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Efficacy and safety of Isa-VRD in the treatment of transplant-ineligible patients with NDMM: Phase III BENEFIT trial
|
Data from the phase III BENEFIT trial (NCT04751877) evaluating the impact of the addition of weekly bortezomib to isatuximab, lenalidomide, and dexamethasone (Isa-VRd) for the treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) were published by Leleu et al.1 in Nature Medicine. The efficacy and safety of Isa-Rd with and without the addition of bortezomib was evaluated. The primary endpoint was measurable residual disease (MRD) benefit at 18 months post randomization. |
| Key learnings: |
|
At 18 months, the MRD negativity rate at ×10-5 was higher in the Isa-VRd arm compared with Isa-Rd arm (53% vs 26%; odds ratio, 3.16; 95% confidence interval, 1.89–5.28; p < 0.0001). |
|
Very good partial response and complete response or better was higher with Isa-VRd compared with Isa-Rd (58% vs 31%; odds ratio, 2.97; 95% confidence interval, 2–5; p < 0.0001). |
|
Neutropenia was the most common adverse event reported in both cohorts.
|
|
Thrombocytopenia was more frequent in patients treated with Isa-VRd compared with those treated with Isa-Rd (27% vs 14%). |
|
Neuropathy was more common in patients treated with Isa-VRd compared with those treated with Isa-Rd (52% vs 28%).
|
|
Isa-VRd demonstrated higher rates of MRD negativity and deeper levels of response, highlighting the potential of Isa-VRd as a new standard of care treatment for transplant-ineligible patients with NDMM. |
- Leleu X, Hulin C, Lambert J, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature Medicine. 2024. Online ahead of print. DOI: 1038/s41591-024-03050-2
Your opinion matters
35 votes - 37 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox